<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04513340</url>
  </required_header>
  <id_info>
    <org_study_id>WD-1603-1002</org_study_id>
    <nct_id>NCT04513340</nct_id>
  </id_info>
  <brief_title>WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects</brief_title>
  <official_title>AN OPEN LABEL, BALANCED, RANDOMISED, FOUR-TREATMENT, FOUR-PERIOD, FOUR-SEQUENCE, SINGLE INTRA-ORAL AND ORAL DOSE, CROSSOVER PHARMACOKINETICS STUDY OF WD-1603 EXTENDED-RELEASE CARBIDOPA/LEVODOPA TABLETS 25/100MG IN NORMAL, HEALTHY, ADULT HUMAN SUBJECTS UNDER FASTING AND FED CONDITIONS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hong Kong WD Pharmaceutical Co., Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hong Kong WD Pharmaceutical Co., Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase 1 PK study is planned to evaluate the food effect on WD-1603 pharmacokinetics&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2020</start_date>
  <completion_date type="Anticipated">February 13, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 5, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1 and Day 2</time_frame>
    <description>Pharmacokinetics Measurements to Determine Cmax for Carbidopa (CD) and Levodopa (LD) Plasma Concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Day 1 and Day 2</time_frame>
    <description>Pharmacokinetics Measurements to Determine AUC0-t for Carbidopa (CD) and Levodopa (LD) Plasma Concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>Day 1 and Day 2</time_frame>
    <description>Pharmacokinetics Measurements to Determine AUC0-∞ for Carbidopa (CD) and Levodopa (LD) Plasma Concentrations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 1 and Day 2</time_frame>
    <description>Pharmacokinetics Measurements to Determine Tmax for Carbidopa (CD) and</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Day 1 and Day 2</time_frame>
    <description>Pharmacokinetics Measurements to Determine t1/2 for Carbidopa (CD) and</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A will be given under fed conditions by intra-oral single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment B will be given intra-orally and orally under fed conditions by single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment C will be given orally under fed conditions by single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment D will be given orally under fasting conditions by single dose administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS</intervention_name>
    <description>CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Normal, healthy adult human volunteers between 18 to 45 years of age (both inclusive).&#xD;
&#xD;
          2. Having a Body Mass Index (BMI) between 18.5 to 29.9 (both inclusive), calculated as&#xD;
             weight in kg / height in m2.&#xD;
&#xD;
          3. Not having any significant disease or clinically significant abnormal findings during&#xD;
             screening, medical history, clinical examination, laboratory evaluations, 12- lead ECG&#xD;
             and X-ray chest (P/A view) recordings.&#xD;
&#xD;
          4. Able to understand and comply with the study procedures, in the opinion of the&#xD;
             principal investigator.&#xD;
&#xD;
          5. Able to give voluntary written informed consent for participation in the trial.&#xD;
&#xD;
          6. In case of female subjects:&#xD;
&#xD;
        a. Surgically sterilized at least 6 months prior to study participation or If of child&#xD;
        bearing potential is willing to use a suitable and effective double barrier contraceptive&#xD;
        method or intra uterine device during the study.&#xD;
&#xD;
        And b. Serum Pregnancy test must be negative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity or idiosyncratic reaction to Carbidopa or Levodopa or any of&#xD;
             the excipients or any related drug.&#xD;
&#xD;
          2. History or presence of any disease or condition which might compromise the&#xD;
             haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular,&#xD;
             immunological, dermatological, gastrointestinal or any other body system.&#xD;
&#xD;
          3. Ingestion of a medicine (prescribed &amp; over the counter (OTC) medication including&#xD;
             herbal remedies) at any time within 14 days before dosing in Period I. In any such&#xD;
             case subject selection will be at the discretion of the Principal Investigator.&#xD;
&#xD;
          4. Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or&#xD;
             NSAIDs induced urticaria.&#xD;
&#xD;
          5. Use of any recreational drugs or history of drug addiction or testing positive in&#xD;
             pre-study drug scans.&#xD;
&#xD;
          6. A recent history of harmful use of alcohol (less than 2 years), i.e. alcohol&#xD;
             consumption of more than 14 standard drinks per week for men and more than 7 standard&#xD;
             drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of&#xD;
             wine or 45 ml of 40% distilled spirits, such as rum, whisky, brandy etc) or&#xD;
             consumption of alcohol or alcoholic products within 48 hours prior to dosing in Period&#xD;
             I.&#xD;
&#xD;
          7. Smokers, who smoke 10 or more than 10 cigarettes / day or inability to abstain from&#xD;
             smoking during the study.&#xD;
&#xD;
          8. The presence of clinically significant abnormal laboratory values during screening.&#xD;
&#xD;
          9. History or presence of psychiatric disorders.&#xD;
&#xD;
         10. A history of difficulty in donating blood.&#xD;
&#xD;
         11. Donation of blood (1 unit or 350 mL) within a period of 90 days prior to the first&#xD;
             dose of study medication.&#xD;
&#xD;
         12. Receipt of an investigational medicinal product or participation in a drug research&#xD;
             study within a period of 90 days prior to the first dose of study medication**.&#xD;
&#xD;
             ** If investigational medicinal product is received within 90 days where there is no&#xD;
             blood loss except safety lab testing, subject can be included considering 10&#xD;
             half-lives duration of investigational medicinal product received.&#xD;
&#xD;
         13. A positive hepatitis screen including hepatitis B surface antigen and/or HCV&#xD;
             antibodies.&#xD;
&#xD;
         14. A positive test result for HIV (1 &amp;/or 2) antibody.&#xD;
&#xD;
         15. An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to&#xD;
             receiving the study medicine in period I. In any such case subject selection will be&#xD;
             at the discretion of the Principal Investigator.&#xD;
&#xD;
         16. Consumption of grapefruit or grapefruit products within 72 hours prior to dosing in&#xD;
             period-I.&#xD;
&#xD;
         17. Difficulty in swallowing oral solid dosage form like tablets or capsules.&#xD;
&#xD;
         18. Nursing mothers (females).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaoxiong Wei, Doctor</last_name>
    <phone>+86-21-6859-9718</phone>
    <email>xiaoxiong.wei@wdpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lambda Therapeutic Research Ltd.</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alpesh Jaswantlal Parmar, Doctor</last_name>
      <phone>+ 91-79-40202020</phone>
      <email>alpeshjparmar@lambda-cro.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

